drug
FULVESTRANT
Marketedupdated 6mo agoby Eagle Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(4)
Trials studying FULVESTRANT
- phase1A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
- phase1A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- phase2Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- phase1A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
- phase1A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
- phase3Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- —A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- phase1A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 14, 2034
~7.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- May 17, 2034formulationUS 9271990
- Feb 14, 2034formulationUS 10188663
- Feb 14, 2034formulationUS 9833459
News(10)
- Roche breast cancer pill cleared by FDAWilserdly’s U.S. approval is seen by analysts as a “key first step” in an important launch for Roche, which has claimed the drug could become its top-selling product.biopharma_dive · 5h ago
- AstraZeneca’s newly approved pill fails frontline breast cancer studyEtcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.biopharma_dive · 2mo ago
- Celcuity gains FDA approval for closely watched breast cancer drugStill, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.biopharma_dive · 4mo ago
- Celcuity wins approval for breast cancer drug RevtorpykA small public biotech won approval for a breast cancer drug that was designed to improve on similar treatments from Novartis and Roche. The FDA on Tuesday cleared Celcuity's Revtorpyk in combinati…endpoints · 4mo ago
- Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast CancerBreast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.onclive · 6mo ago
- Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast CancerKelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.onclive · 6mo ago
- Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie BondDr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.onclive · 6mo ago
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.onclive · 6mo ago
- MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine TumorsRoswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.onclive · 6mo ago
- Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCTR. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.onclive · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that